SCHEMBL8621668

SCHEMBL8621668

OC(c1ccccc1)(c1ccccc1)[C@H]1CCN1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.79
MAPK1 P28482 2/20 0.79
KDM4E B2RXH2 1/20 0.79
NPC1 O15118 1/20 0.79
CYP1A2 P05177 1/20 0.79
HPGD P15428 1/20 0.79
CYP2C19 P33261 1/20 0.79
RAB9A P51151 1/20 0.79
LMNA P02545 3/20 0.58
HRH1 P35367 2/20 0.58
MEN1 O00255 1/20 0.58
SCN1A P35498 1/20 0.58
KMT2A Q03164 1/20 0.58
SCN2A Q99250 1/20 0.58
SCN3A Q9NY46 1/20 0.58
CHRM3 P20309 1/20 0.43
CYP3A4 P08684 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
APOBEC3A P31941 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6295242 1.00 CYP2D6 (0.79) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL5054811 1.00 CYP2D6 (0.79) CYP2D6MAPK1KDM4ENPC1CYP1A2
Hydrochloric Acid SCHEMBL9231013 0.98 CYP2D6 (0.83) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL100360 0.90 CYP2D6 (0.96) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL100361 0.90 CYP2D6 (0.96) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL239738 0.90 CYP2D6 (0.96) CYP2D6MAPK1KDM4ENPC1CYP1A2
Pipradrol SCHEMBL156360 0.89 CYP2D6 (0.87) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL8136171 0.89 CYP2D6 (0.93) CYP2D6MAPK1KDM4ENPC1CYP1A2
Hydrochloric Acid SCHEMBL9277459 0.89 CYP2D6 (1.00) CYP2D6MAPK1KDM4ENPC1CYP1A2
SCHEMBL7446968 0.89 CYP2D6 (0.93) CYP2D6MAPK1KDM4ENPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
US-5830468-A Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase THE NEW YORK BLOOD CENTER, INC. (US) 1998-11-03 US disclosed
EP-0713880-B1 Stereoselective reduction of 17-ketosteroids JENAPHARM GMBH (DE) 1998-06-10 EP disclosed
EP-0713880-A2 Stereoselective reduction of 17-ketosteroids JENAPHARM GmbH (DE) 1996-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 CYP2D6 1125/4885MAPK1 1954/4885KDM4E 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.